ABCELLERA BIOLOGICS Cash Flow-to-Debt Ratio
ABCELLERA BIOLOGICS cash flow-to-debt ratio. ABCELLERA BIOLOGICS (8QQ) has a Cash Flow-to-Debt Ratio of 0.06x as of June 2026, meaning its operating cash flow of €25.92 Million could theoretically repay 0% of its total liabilities (€411.56 Million) in one year. Check 8QQ cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of ABCELLERA BIOLOGICS (2021–2025)
Cash flow-to-debt ratio of ABCELLERA BIOLOGICS from 2021 to 2025. Historical debt coverage capacity for ABCELLERA BIOLOGICS across 5 annual periods. Check 8QQ capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
ABCELLERA BIOLOGICS Cash Flow-to-Debt Ratio by Year (2021–2025)
ABCELLERA BIOLOGICS cash flow-to-debt ratio by year from 2021 to 2025. Year-by-year debt coverage analysis for ABCELLERA BIOLOGICS. For the full cash flow conversion analysis, see cash efficiency ratio of ABCELLERA BIOLOGICS.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.34x | €-131.29 Million | €390.05 Million | ▲ +5.6% |
| 2024 | -0.36x | €-108.56 Million | €304.47 Million | ▼ -172.8% |
| 2023 | -0.13x | €-43.88 Million | €335.78 Million | ▼ -114.5% |
| 2022 | 0.90x | €277.36 Million | €307.63 Million | ▲ +7.9% |
| 2021 | 0.84x | €244.58 Million | €292.84 Million | — |